FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126087173> ?p ?o ?g. }

• W2126087173 endingPage "S5" @default.
• W2126087173 startingPage "S5" @default.
• W2126087173 abstract "Pain is among the worst possible experiences for the critically ill. Therefore, nearly all intensive care patients receive some kind of pain relief, and opioids are most frequently administered. Morphine has a number of important adverse effects, including histamine release, pruritus, constipation, and, in particular, accumulation of morphine-6-glucuronide in patients with renal impairment. Hence, it is not an ideal analgesic for use in critically ill patients. Although the synthetic opioids fentanyl, alfentanil, and sufentanil have better profiles, they undergo hepatic metabolism and their continuous infusion also leads to accumulation and prolonged drug effects. Various attempts have been made to limit these adverse effects, including daily interruption of infusion of sedatives and analgesics, intermittent bolus injections rather than continuous infusions, and selection of a ventilatory support pattern that allows more spontaneous ventilation. However, these techniques at best only limit the effects of drug accumulation, but they do not solve the problem. Another type of approach is to use remifentanil in critically ill patients. Remifentanil is metabolized by unspecific blood and tissue esterases and undergoes rapid metabolism, independent of the duration of infusion or any organ insufficiency. There are data indicating that remifentanil can be used for analgesia and sedation in all kinds of adult intensive care unit patients, and that its use will result in rapid and predictable offset of effect. This may permit both a significant reduction in weaning and extubation times, and clear differentiation between over-sedation and brain dysfunction. This article provides an overview of the use of short-acting opioids in the intensive care unit, with special emphasis on remifentanil. It summarizes the currently available study data regarding remifentanil and provides recommendations for clinical use of this agent." @default.
• W2126087173 created "2016-06-24" @default.
• W2126087173 creator A5058563419 @default.
• W2126087173 creator A5087173189 @default.
• W2126087173 date "2008-01-01" @default.
• W2126087173 modified "2023-10-03" @default.
• W2126087173 title "The place for short-acting opioids: special emphasis on remifentanil" @default.
• W2126087173 cites W1535551809 @default.
• W2126087173 cites W1545845849 @default.
• W2126087173 cites W1665388663 @default.
• W2126087173 cites W1687966516 @default.
• W2126087173 cites W1974372062 @default.
• W2126087173 cites W1979288067 @default.
• W2126087173 cites W1981813046 @default.
• W2126087173 cites W1981844489 @default.
• W2126087173 cites W1998605059 @default.
• W2126087173 cites W1999048227 @default.
• W2126087173 cites W2007818846 @default.
• W2126087173 cites W2009076067 @default.
• W2126087173 cites W2024951267 @default.
• W2126087173 cites W2043121641 @default.
• W2126087173 cites W2052996321 @default.
• W2126087173 cites W2056563604 @default.
• W2126087173 cites W2091949720 @default.
• W2126087173 cites W2102347034 @default.
• W2126087173 cites W2112634018 @default.
• W2126087173 cites W2121404152 @default.
• W2126087173 cites W2124545707 @default.
• W2126087173 cites W2134210134 @default.
• W2126087173 cites W2144351082 @default.
• W2126087173 cites W2146726027 @default.
• W2126087173 cites W2147770670 @default.
• W2126087173 cites W2149306268 @default.
• W2126087173 cites W2156598086 @default.
• W2126087173 cites W2322707526 @default.
• W2126087173 cites W248794154 @default.
• W2126087173 doi "https://doi.org/10.1186/cc6152" @default.
• W2126087173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2391266" @default.
• W2126087173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18495056" @default.
• W2126087173 hasPublicationYear "2008" @default.
• W2126087173 type Work @default.
• W2126087173 sameAs 2126087173 @default.
• W2126087173 citedByCount "78" @default.
• W2126087173 countsByYear W21260871732012 @default.
• W2126087173 countsByYear W21260871732013 @default.
• W2126087173 countsByYear W21260871732014 @default.
• W2126087173 countsByYear W21260871732015 @default.
• W2126087173 countsByYear W21260871732016 @default.
• W2126087173 countsByYear W21260871732017 @default.
• W2126087173 countsByYear W21260871732018 @default.
• W2126087173 countsByYear W21260871732019 @default.
• W2126087173 countsByYear W21260871732020 @default.
• W2126087173 countsByYear W21260871732021 @default.
• W2126087173 countsByYear W21260871732022 @default.
• W2126087173 countsByYear W21260871732023 @default.
• W2126087173 crossrefType "journal-article" @default.
• W2126087173 hasAuthorship W2126087173A5058563419 @default.
• W2126087173 hasAuthorship W2126087173A5087173189 @default.
• W2126087173 hasBestOaLocation W21260871731 @default.
• W2126087173 hasConcept C126322002 @default.
• W2126087173 hasConcept C170493617 @default.
• W2126087173 hasConcept C177713679 @default.
• W2126087173 hasConcept C197934379 @default.
• W2126087173 hasConcept C2776277131 @default.
• W2126087173 hasConcept C2776376669 @default.
• W2126087173 hasConcept C2776814716 @default.
• W2126087173 hasConcept C2777019824 @default.
• W2126087173 hasConcept C2777389121 @default.
• W2126087173 hasConcept C2778891214 @default.
• W2126087173 hasConcept C2779158186 @default.
• W2126087173 hasConcept C2781063702 @default.
• W2126087173 hasConcept C2781072394 @default.
• W2126087173 hasConcept C2781091344 @default.
• W2126087173 hasConcept C2987404301 @default.
• W2126087173 hasConcept C42219234 @default.
• W2126087173 hasConcept C71924100 @default.
• W2126087173 hasConcept C98274493 @default.
• W2126087173 hasConceptScore W2126087173C126322002 @default.
• W2126087173 hasConceptScore W2126087173C170493617 @default.
• W2126087173 hasConceptScore W2126087173C177713679 @default.
• W2126087173 hasConceptScore W2126087173C197934379 @default.
• W2126087173 hasConceptScore W2126087173C2776277131 @default.
• W2126087173 hasConceptScore W2126087173C2776376669 @default.
• W2126087173 hasConceptScore W2126087173C2776814716 @default.
• W2126087173 hasConceptScore W2126087173C2777019824 @default.
• W2126087173 hasConceptScore W2126087173C2777389121 @default.
• W2126087173 hasConceptScore W2126087173C2778891214 @default.
• W2126087173 hasConceptScore W2126087173C2779158186 @default.
• W2126087173 hasConceptScore W2126087173C2781063702 @default.
• W2126087173 hasConceptScore W2126087173C2781072394 @default.
• W2126087173 hasConceptScore W2126087173C2781091344 @default.
• W2126087173 hasConceptScore W2126087173C2987404301 @default.
• W2126087173 hasConceptScore W2126087173C42219234 @default.
• W2126087173 hasConceptScore W2126087173C71924100 @default.
• W2126087173 hasConceptScore W2126087173C98274493 @default.
• W2126087173 hasIssue "Suppl 3" @default.
• W2126087173 hasLocation W21260871731 @default.
• W2126087173 hasLocation W21260871732 @default.

• next